COMP <GO>
LFMD vs ABBV // GROSS PROFIT MARGIN
LifeMD Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: LFMD 4
— ABBV 7
▲ GROSS PROFIT MARGIN LEADER: LFMD
LAST: $2.32 (+4.04%) • MKT CAP: $111.8M
gross-margins
85.70%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LFMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LFMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 85.70% | 70.20% | +15.50 | LFMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -26.20% | 29.00% | -55.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.73% | 3.47% | +2.26 | LFMD | /fcf-yield <GO> |
| Operating Margin | -4.00% | 24.60% | -28.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -5.80% | 6.90% | -12.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 25.30% | 8.60% | +16.70 | LFMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.78% | 2.27% | +0.51 | LFMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.8 | 65.1 | -26.35 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $111.8M | $513.86B | -$513.75B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LFMD REV | ABBV REV | LFMD GROSS % | ABBV GROSS % | LFMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $194.1M | $61.16B | 85.7% | 70.2% | $6.4M | $17.82B |
| FY 2024 | $154.8M | $56.33B | 86.2% | 70.0% | $16.0M | $17.83B |
| FY 2023 | $152.5M | $54.32B | — | — | $8.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LFMD // BETA —
ABBV // BETA 1.15